Manuel Campolini

Manuel primarily focuses his practice on legal assistance and litigation in relation to pharmaceutical issues and IP issues at both a national and European level.

In these areas, Manuel has a breadth of knowledge and expertise in related areas of pharma law consisting of products life-cycle management, regulatory, bio-technology, pricing and advertising, but also audio-visual, comic strips and merchandising, as well as IPs global strategy in relation to financial services and products.

Up to 2004, Manuel was in-house counsel, and later an outside counsel, of the EFPIA in a number of legal issues such as the adoption of the new EU pharmaceutical legislation.

As a specialist in pharma and IP  law, Manuel is also frequently invited to speak at conferences in his areas of competence.

  • Languages: French, English, Italian, German
  • Admitted to the Brussels Bar: 1989

Experience

Related news

20.02.2017 BE law
New Belgian tax incentive for innovation income adopted

Articles - Today, 20 February 2017, a law introducing a new tax incentive for “innovation income” is published in the Belgian Official Gazette. The new incentive replaces the former Belgian patent income deduction, that was abolished as from 1 July 2016 due to not being fully compliant with the OECD BEPS recommendations.

Read more

27.06.2016 BE law
The International Comparative Legal Guide to: Pharmaceutical Advertising 2016 – Belgium Chapter

Articles - ICLG’s International Comparative Legal Guide to: Pharmaceutical Advertising 2016 provides corporate counsel and international practitioners with a comprehensive worldwide legal analysis of pharmaceutical advertising laws and regulations, including advertisements to healthcare professionals, gifts and financial incentives, and so on.

Read more

24.06.2016 BE law
UK’s referendum — its implication on the Unitary Patent System

Trends - Yesterday, on 23rd June 2016, the United Kingdom has decided, through a public referendum, to leave the European Union.  Aside from the many other consequences of this vote, the decision also has a direct impact on the Unitary Patent/Unified Patent Court system because this new system is not open for participation of a non-EU member state.

Read more

Other specialists

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy